Chinese expert consensus on the prevention and treatment of venous thromboembolism in the elderly_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHAO Jichun ,  ZHAO Yu ,  ZHANG Lan ,  HUANG Jianhua ,  GUO Pingfan ,  WANG Tao ,  LI Yongjun ,  WANG Haiyang ,  CHEN Quan

Peripheral Vascular Disease Management Branch of the Chinese Geriatrics Society;

Corresponding author：

ZHAO Jichun, Email: zhaojc3@126.com; ZHAO Yu, Email: 820994765@qq.com; ZHANG Lan, Email: lucky200207@aliyun.com; HUANG Jianhua, Email: 13507319258@139.com; GUO Pingfan, Email: fjxgguo@126.com; WANG Tao, Email: 794479116@qq.com; LI Yongjun, Email: liyongjun4679@bjhmoh.cn; WANG Haiyang, Email: wanghaiyangguan@163.com; CHEN Quan, Email: 13919093907@126.com

Keywords：

venous thromboembolism; diagnosis; prevention; treatment; elderly people; elderly care institution

DOI：

10.7507/1007-9424.202308048

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The incidence of venous thromboembolism (VTE) is relatively high in the elderly population, and the disability, mortality, and medical expenses caused by VTE are also high. However, in a large number of randomized controlled and non-randomized controlled studies related to VTE, sufficient attention has not been paid to the elderly population with multiple underlying diseases. Therefore, the vast majority of research results recommended by VTE guidelines come from younger patients and healthy elderly people, at the same time, most relevant VTE prevention and treatment guidelines or consensus are formulated for hospitalized patients, and for non-hospital elderly populations such as home and elderly care institutions that truly need attention and risk of VTE, their recommended opinions are uncertain. In this context, the Peripheral Vascular Disease Management Branch of the Chinese Geriatrics Society has developed a consensus among Chinese experts on the prevention and treatment of VET in the elderly, based on evidence-based evidence such as domestic and foreign guidelines and relevant research.

Citation： ZHAO Jichun, ZHAO Yu, ZHANG Lan, HUANG Jianhua, GUO Pingfan, WANG Tao, LI Yongjun, WANG Haiyang, CHEN Quan. Chinese expert consensus on the prevention and treatment of venous thromboembolism in the elderly. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2023, 30(10): 1173-1187. doi: 10.7507/1007-9424.202308048 Copy

1.	Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost, 2007, 5(4): 692-699.
2.	Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost, 2008, 100(5): 780-788.
3.	Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med, 2013, 126(9): 832.e13-e21. doi: 10.1016/j.amjmed.2013.02.024.
4.	Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med, 2000, 160(6): 761-768.
5.	LaMori JC, Shoheiber O, Mody SH, et al. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther, 2015, 37(1): 62-70.
6.	Silverstein RL, Bauer KA, Cushman M, et al. Venous thrombosis in the elderly: more questions than answers. Blood, 2007, 110(9): 3097-3101.
7.	Link RP. National Heart, Lung, and Blood Institute programs for deep vein thrombosis. Arterioscler Thromb Vasc Biol, 2008, 28(3): 392-393.
8.	Méan M, Righini M, Jaeger K, et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis, 2013, 36(4): 475-483.
9.	Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation, 2011, 124(7): 824-829.
10.	Spencer FA, Gurwitz JH, Schulman S, et al. Venous thromboembolism in older adults: a community-based study. Am J Med, 2014, 127(6): 530-537.
11.	López-Jiménez L, Montero M, González-Fajardo JA, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica, 2006, 91(8): 1046-1051.
12.	中华医学会外科学分会血管外科学组. 深静脉血栓形成的诊断和治疗指南 (第三版). 中国血管外科杂志 (电子版), 2017, 9(4): 250-257.
13.	静脉血栓栓塞症抗凝治疗微循环血栓防治共识专家组. 静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识. 中华老年多器官疾病杂志, 2017, 16(4): 241-244.
14.	陈磊, 吴剑卿. 老年肺栓塞诊治进展. 中华老年病研究电子杂志, 2015, 2(4): 24-30.
15.	Palareti G, Poli D. The prevention of venous thromboembolism recurrence in the elderly: a still open issue. Expert Rev Hematol, 2018, 11(11): 903-909.
16.	贾奇柯, 孔瑞泽, 张承磊, 等. 静脉血栓栓塞症的流行病学. 中国血管外科杂志 (电子版), 2013, 5(1): 62-64.
17.	Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatr Soc, 2016, 64(9): 1869-1878.
18.	Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med, 2010, 38(4 Suppl): S495-S501.
19.	Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol, 2015, 12(8): 464-474.
20.	White RH. The epidemiology of venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): I4-I8.
21.	Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med, 2014, 127(9): 829-839. e5.
22.	Yang Y, Liang L, Zhai Z, et al. Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One, 2011, 6(11): e26861. doi:10.1371/journal.pone.0026861.
23.	Huang D, Chan PH, She HL, et al. Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016. Thromb Res, 2018, 166: 80-85.
24.	Tritschler T, Aujesky D. Venous thromboembolism in the elderly: a narrative review. Thromb Res, 2017, 155: 140-147.
25.	Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98(4): 756-764.
26.	温绍君, 刘洁琳. 静脉血栓栓塞症的流行病学. 中华老年心脑血管病杂志, 2010, 12(11): 961-963.
27.	张劲松, 李琳. 老年人静脉血栓栓塞症的流行病学. 实用老年医学, 2013, 27(10): 806-809.
28.	Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14.
29.	孙全义. 老年人静脉血栓栓塞的研究现状. 中国伤残医学, 2012, 20(2): 110-111.
30.	李小鹰. 内科住院患者深静脉血栓栓塞的风险与防治. 中国实用内科杂志, 2011, 31(1): 34-35.
31.	区满春, 曾敏怡, 石任任, 等. 静脉血栓栓塞症高危因素和临床表现的荟萃分析. 诊断学理论与实践, 2011, 10(2): 113-116.
32.	Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med, 2012, 9(7): e1001275. doi: 10.1371/journal.pmed.1001275.
33.	Tritschler T, Castellucci LA, Van Es N, et al. Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants. Pol Arch Intern Med, 2020, 130(6): 529-538.
34.	Shakeel M, Thachil J. Dilemmas in the management of venous thromboembolism in older patients. Br J Hosp Med (Lond), 2017, 78(10): 552-557.
35.	易巍, 徐岩. 老年急性下肢深静脉血栓症患者的临床表现分析. 中国老年保健医学, 2011, 9(2): 14-15.
36.	栾景源, 董国祥. 老年人下肢深静脉血栓形成的临床特点. 中华老年医学杂志, 2009, 28(3): 217-220.
37.	柏志斌, 秦永林, 邓钢, 等. 青年及中老年患者下肢深静脉血栓形成的临床特征及危险因素对比分析. 中国现代医学杂志, 2015, 25(12): 102-105.
38.	Visonà A, Quere I, Mazzolai L, et al. Post-thrombotic syndrome. Vasa, 2021, 50(5): 331-340.
39.	欧永强, 吴容展, 潘华福. 老年肺血栓栓塞症患者的临床症状和体征表现分析. 中国当代医药, 2011, 18(8): 177-180.
40.	Kokturk N, Oguzulgen IK, Demir N, et al. Differences in clinical presentation of pulmonary embolism in older vs younger patients. Circ J, 2005, 69(8): 981-986.
41.	Kiluk IE, Krajewska A, Kosacka U, et al. Different manifestations of pulmonary embolism in younger compared to older patients: Clinical presentation, prediction rules and long-term outcomes. Adv Med Sci, 2017, 62(2): 254-258.
42.	Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on themanagement of venous thrombosis. Eur J Vasc Endovasc Surg, 2021, 61(1): 9-82.
43.	Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013, 369(9): 799-808.
44.	Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340. doi: 10.1136/bmj.g1340.
45.	Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480.
46.	Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20.
47.	Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181.
48.	Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234.
49.	García-Fuster MJ, Fabia MJ, Furió E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178. doi: 10.1186/1471-2261-14-178.
50.	Stein PD, Matta F, Musani MH, et al. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med, 2010, 123(5): 426-431.
51.	Prandoni P, Lensing AW, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med, 1992, 327(16): 1128-1133.
52.	Delluc A, Ianotto JC, Tromeur C, et al. Real-world incidence of cancer following a first unprovoked venous thrombosis: results from the EPIGETBO study. Thromb Res, 2018, 164: 79-84.
53.	Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thromb Res, 2017, 157: 147-153.
54.	Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80.
55.	Robin P, Otten HM, Delluc A, et al. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thromb Res, 2018, 171: 92-96.
56.	Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res, 2005, 116(4): 301-306.
57.	Stern RM, Al-Samkari H, Connors JM. Thrombophilia evaluation in pulmonary embolism. Curr Opin Cardiol, 2019, 34(6): 603-609.
58.	Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80.
59.	Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187.
60.	Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med, 2004, 140(8): 589-602.
61.	Gibson NS, Sohne M, Kruip MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost, 2008, 99(1): 229-234.
62.	Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost, 2010, 8(5): 957-970.
63.	van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet, 2017, 390(10091): 289-297.
64.	Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med, 2001, 135(2): 98-107.
65.	van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA, 2006, 295(2): 172-179.
66.	Kruip MJ, Slob MJ, Schijen JH, et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med, 2002, 162(14): 1631-1635.
67.	Perrier A, Roy PM, Aujesky D, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med, 2004, 116(5): 291-299.
68.	Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost, 2007, 5(2): 296-304.
69.	Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 2014, 311(11): 1117-1124.
70.	van Es N, van der Hulle T, van Es J, et al. Wells rule and D-dimer testing to rule out pulmonary embolism: a systematic review and individual-patient data meta-analysis. Ann Intern Med, 2016, 165(4): 253-261.
71.	Parry BA, Chang AM, Schellong SM, et al. International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thromb Res, 2018, 166: 63-70.
72.	Farm M, Siddiqui AJ, Onelöv L, et al. Age-adjusted D-dimer cut-off leads to more efficient diagnosis of venous thromboembolism in the emergency department: a comparison of four assays. J Thromb Haemost, 2018, 16(5): 866-875.
73.	Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost, 2000, 83(3): 416-420.
74.	Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med, 2006, 144(3): 165-171.
75.	Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med, 2008, 168(19): 2131-2136.
76.	Jimenez D, Lobo JL, Fernandez-Golfin C, et al. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. Thromb Haemost, 2016, 115(4): 827-834.
77.	Hobohm L, Hellenkamp K, Hasenfuß G, et al. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. Eur Respir J, 2016, 47(4): 1170-1178.
78.	Becattini C, Agnelli G, Lankeit M, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J, 2016, 48(3): 780-786.
79.	Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J, 2008, 29(18): 2276-2315.
80.	Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J, 2019, 54(3): 1901647. doi: 10.1183/13993003.01647-2019.
81.	Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med, 2005, 172(8): 1041-1046.
82.	Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med, 2010, 170(15): 1383-1389.
83.	Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood, 2008, 111(9): 4471-4476.
84.	Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 2016, 149(2): 315-352.
85.	Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med, 2005, 118(6): 625-635.
86.	Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost, 2013, 11(6): 1053-1058.
87.	Scherz N, Méan M, Limacher A, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost, 2013, 11(3): 435-443.
88.	Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med, 2015, 30(1): 17-24.
89.	Frey PM, Méan M, Limacher A, et al. Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost, 2015, 13(2): 197-205.
90.	Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med, 2012, 125(8): 773-778.
91.	Kämpfen P, Méan M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med, 2014, 276(4): 378-386.
92.	Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ, 2016, 6(2): 145-154.
93.	van Es J, den Exter PL, Kaptein AA, et al. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res, 2013, 132(5): 500-505.
94.	Tavoly M, Utne KK, Jelsness-Jørgensen LP, et al. Health-related quality of life after pulmonary embolism: a cross-sectional study. BMJ Open, 2016, 6(11): e013086. doi: 10.1136/bmjopen-2016-013086.
95.	Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation, 2014, 130(18): 1636-1661.
96.	柳志红. 2019欧洲心脏病学会《急性肺栓塞诊断和治疗指南》解读. 中国循环杂志, 2019, 34(12): 1155-1157.
97.	Cyrino FZ, Bottino DA, Lerond L, et al. Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch. Clin Exp Pharmacol Physiol, 2004, 31(3): 159-162.
98.	Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology, 2001, 52 Suppl 1: S43-S47.
99.	Shoab SS, Porter J, Scurr JH, et al. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease—a prospective study. Eur J Vasc Endovasc Surg, 1999, 17(4): 313-318.
100.	国际血管联盟中国分会, 中国老年医学学会周围血管疾病管理分会. 输液导管相关静脉血栓形成防治中国专家共识(2020版). 中国实用外科杂志, 2020, 40(4): 377-383.
101.	Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565.
102.	《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南. 中华医学杂志, 2018, 98(36): 2861-2888.
103.	Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis, 2016, 41(1): 32-67.
104.	傅麒宁, 吴洲鹏, 孙文彦, 等. 《输液导管相关静脉血栓形成中国专家共识》临床实践推荐. 中国普外基础与临床杂志, 2020, 27(4): 412-418.
105.	Xu Y, Wang W, Zhao J, et al. Knowledge, attitude, and practice of healthcare professionals toward clinically applying graduated compression stockings: results of a Chinese web-based survey. J Thromb Thrombolysis, 2019, 47(1): 102-108.
106.	Lattimer CR, Kalodiki E, Azzam M, et al. Haemodynamic performance of low strength below knee graduated elastic compression stockings in health, venous disease, and lymphoedema. Eur J Vasc Endovasc Surg, 2016, 52(1): 105-112.
107.	Ito T, Kukino R, Takahara M, et al. The wound/burn guidelines - 5: guidelines for the management of lower leg ulcers/varicose veins. J Dermatol, 2016, 43(8): 853-868.
108.	YY/T 0851-2011. 中华人民共和国医药行业标准: 医用防血栓袜. 国家食品药品监督管理局, 2011.
109.	Azirar S, Appelen D, Prins MH, et al. Compression therapy for treating post-thrombotic syndrome. Cochrane Database Syst Rev, 2019, 9(9): CD004177. doi: 10.1002/14651858.CD004177.pub2.
110.	Rabe E, Partsch H, Hafner J, et al. Indications for medical compression stockings in venous and lymphatic disorders: an evidence-based consensus statement. Phlebology, 2018, 33(3): 163-184.
111.	National Guideline Centre (UK). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. National Institute for Health and Care Excellence (NICE), 2019.
112.	许晓岩, 杨媛华, 王辰. 老年人肺血栓栓塞症的临床表现与分析. 中华老年心脑血管病杂志, 2006, 8(10): 665-667.
113.	Lee SY, Ro du H, Chung CY, et al. Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J, 2015, 56(1): 139-145.
114.	British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax, 2003, 58(6): 470-483.
115.	Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost, 2010, 8(10): 2105-2112.
116.	Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation, 2015, 132(3): 194-204.
117.	Karamichalakis N, Georgopoulos S, Vlachos K, et al. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol, 2016, 13(8): 718-723.
118.	Bartholomew JR. Update on the management of venous thromboembolism. Cleve Clin J Med, 2017, 84(12 Suppl 3): 39-46.
119.	Lee KA, Ramaswamy RS. Interventional approaches to deep venous thrombosis. Curr Opin Cardiol, 2017, 32(6): 679-686.
120.	CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. Ann Intern Med, 2010, 153(9): 553-562.
121.	Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J, 1981, 26(2): 115-117.
122.	Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med, 1982, 10(7): 448-450.
123.	Kapoor M, Kupfer YY, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in tlle critically ill. Crit Care Med, 1999, 27 Suppl: A69. doi: 10.1097/00003246-199912001-00165.
124.	Phung OJ, Kahn SR, Cook DJ, et al. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest, 2011, 140(2): 374-381.
125.	King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a meta analysis. Chest, 2007, 131(2): 507-516.
126.	Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e278S-e325S.
127.	Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med, 2007, 146(4): 278-288.
128.	Che DH, Cao JY, Shang LH, et al. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med, 2013, 24(5): 433-439.
129.	Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med, 2011, 365(23): 2167-2177.
130.	Levine MN, Gu C, Liebman HA, et al. A randomized phase Ⅱ trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost, 2012, 10(5): 807-814.
131.	Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.
132.	Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med, 2013, 368(6): 513-523.
133.	Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage Ⅳ breast cancer. Lancet, 1994, 343(8902): 886-889.
134.	Zhang J, Zhang YL, Ma KX, et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax, 2013, 68(5): 442-450.
135.	Zhang X, Cai Q, Wang X, et al. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis, 2021, 52(3): 863-871.
136.	Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol, 2016, 3(2): e64-e71.
137.	Lichtenberg MKW, Stahlhoff S, Młyńczak K, et al. Eombosis: a single centre retrospective cohort study. Eur J Vasc Endovasc Surg, 2020, 60(4): 578-585.
138.	吴欣择, 李朝阳, 冯松林, 等. 不同治疗方式对老年急性下肢深静脉血栓形成患者的疗效及预后分析. 血管与腔内血管外科杂志, 2021, 7(3): 292-296.

1. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost, 2007, 5(4): 692-699.
2. Spencer FA, Gore JM, Lessard D, et al. Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost, 2008, 100(5): 780-788.
3. Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med, 2013, 126(9): 832.e13-e21. doi: 10.1016/j.amjmed.2013.02.024.
4. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med, 2000, 160(6): 761-768.
5. LaMori JC, Shoheiber O, Mody SH, et al. Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. Clin Ther, 2015, 37(1): 62-70.
6. Silverstein RL, Bauer KA, Cushman M, et al. Venous thrombosis in the elderly: more questions than answers. Blood, 2007, 110(9): 3097-3101.
7. Link RP. National Heart, Lung, and Blood Institute programs for deep vein thrombosis. Arterioscler Thromb Vasc Biol, 2008, 28(3): 392-393.
8. Méan M, Righini M, Jaeger K, et al. The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology. J Thromb Thrombolysis, 2013, 36(4): 475-483.
9. Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation, 2011, 124(7): 824-829.
10. Spencer FA, Gurwitz JH, Schulman S, et al. Venous thromboembolism in older adults: a community-based study. Am J Med, 2014, 127(6): 530-537.
11. López-Jiménez L, Montero M, González-Fajardo JA, et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica, 2006, 91(8): 1046-1051.
12. 中华医学会外科学分会血管外科学组. 深静脉血栓形成的诊断和治疗指南 (第三版). 中国血管外科杂志 (电子版), 2017, 9(4): 250-257.
13. 静脉血栓栓塞症抗凝治疗微循环血栓防治共识专家组. 静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识. 中华老年多器官疾病杂志, 2017, 16(4): 241-244.
14. 陈磊, 吴剑卿. 老年肺栓塞诊治进展. 中华老年病研究电子杂志, 2015, 2(4): 24-30.
15. Palareti G, Poli D. The prevention of venous thromboembolism recurrence in the elderly: a still open issue. Expert Rev Hematol, 2018, 11(11): 903-909.
16. 贾奇柯, 孔瑞泽, 张承磊, 等. 静脉血栓栓塞症的流行病学. 中国血管外科杂志 (电子版), 2013, 5(1): 62-64.
17. Johnson SA, Eleazer GP, Rondina MT. Pathogenesis, diagnosis, and treatment of venous thromboembolism in older adults. J Am Geriatr Soc, 2016, 64(9): 1869-1878.
18. Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med, 2010, 38(4 Suppl): S495-S501.
19. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol, 2015, 12(8): 464-474.
20. White RH. The epidemiology of venous thromboembolism. Circulation, 2003, 107(23 Suppl 1): I4-I8.
21. Huang W, Goldberg RJ, Anderson FA, et al. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med, 2014, 127(9): 829-839. e5.
22. Yang Y, Liang L, Zhai Z, et al. Pulmonary embolism incidence and fatality trends in Chinese hospitals from 1997 to 2008: a multicenter registration study. PLoS One, 2011, 6(11): e26861. doi:10.1371/journal.pone.0026861.
23. Huang D, Chan PH, She HL, et al. Secular trends and etiologies of venous thromboembolism in Chinese from 2004 to 2016. Thromb Res, 2018, 166: 80-85.
24. Tritschler T, Aujesky D. Venous thromboembolism in the elderly: a narrative review. Thromb Res, 2017, 155: 140-147.
25. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98(4): 756-764.
26. 温绍君, 刘洁琳. 静脉血栓栓塞症的流行病学. 中华老年心脑血管病杂志, 2010, 12(11): 961-963.
27. 张劲松, 李琳. 老年人静脉血栓栓塞症的流行病学. 实用老年医学, 2013, 27(10): 806-809.
28. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14.
29. 孙全义. 老年人静脉血栓栓塞的研究现状. 中国伤残医学, 2012, 20(2): 110-111.
30. 李小鹰. 内科住院患者深静脉血栓栓塞的风险与防治. 中国实用内科杂志, 2011, 31(1): 34-35.
31. 区满春, 曾敏怡, 石任任, 等. 静脉血栓栓塞症高危因素和临床表现的荟萃分析. 诊断学理论与实践, 2011, 10(2): 113-116.
32. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med, 2012, 9(7): e1001275. doi: 10.1371/journal.pmed.1001275.
33. Tritschler T, Castellucci LA, Van Es N, et al. Treatment of venous thromboembolism in elderly patients in the era of direct oral anticoagulants. Pol Arch Intern Med, 2020, 130(6): 529-538.
34. Shakeel M, Thachil J. Dilemmas in the management of venous thromboembolism in older patients. Br J Hosp Med (Lond), 2017, 78(10): 552-557.
35. 易巍, 徐岩. 老年急性下肢深静脉血栓症患者的临床表现分析. 中国老年保健医学, 2011, 9(2): 14-15.
36. 栾景源, 董国祥. 老年人下肢深静脉血栓形成的临床特点. 中华老年医学杂志, 2009, 28(3): 217-220.
37. 柏志斌, 秦永林, 邓钢, 等. 青年及中老年患者下肢深静脉血栓形成的临床特征及危险因素对比分析. 中国现代医学杂志, 2015, 25(12): 102-105.
38. Visonà A, Quere I, Mazzolai L, et al. Post-thrombotic syndrome. Vasa, 2021, 50(5): 331-340.
39. 欧永强, 吴容展, 潘华福. 老年肺血栓栓塞症患者的临床症状和体征表现分析. 中国当代医药, 2011, 18(8): 177-180.
40. Kokturk N, Oguzulgen IK, Demir N, et al. Differences in clinical presentation of pulmonary embolism in older vs younger patients. Circ J, 2005, 69(8): 981-986.
41. Kiluk IE, Krajewska A, Kosacka U, et al. Different manifestations of pulmonary embolism in younger compared to older patients: Clinical presentation, prediction rules and long-term outcomes. Adv Med Sci, 2017, 62(2): 254-258.
42. Kakkos SK, Gohel M, Baekgaard N, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on themanagement of venous thrombosis. Eur J Vasc Endovasc Surg, 2021, 61(1): 9-82.
43. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 2013, 369(9): 799-808.
44. Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340. doi: 10.1136/bmj.g1340.
45. Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480.
46. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20.
47. Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181.
48. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234.
49. García-Fuster MJ, Fabia MJ, Furió E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178. doi: 10.1186/1471-2261-14-178.
50. Stein PD, Matta F, Musani MH, et al. Silent pulmonary embolism in patients with deep venous thrombosis: a systematic review. Am J Med, 2010, 123(5): 426-431.
51. Prandoni P, Lensing AW, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med, 1992, 327(16): 1128-1133.
52. Delluc A, Ianotto JC, Tromeur C, et al. Real-world incidence of cancer following a first unprovoked venous thrombosis: results from the EPIGETBO study. Thromb Res, 2018, 164: 79-84.
53. Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: a meta-analysis. Thromb Res, 2017, 157: 147-153.
54. Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80.
55. Robin P, Otten HM, Delluc A, et al. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism. Thromb Res, 2018, 171: 92-96.
56. Santamaria MG, Agnelli G, Taliani MR, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res, 2005, 116(4): 301-306.
57. Stern RM, Al-Samkari H, Connors JM. Thrombophilia evaluation in pulmonary embolism. Curr Opin Cardiol, 2019, 34(6): 603-609.
58. Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80.
59. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187.
60. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: a systematic review. Ann Intern Med, 2004, 140(8): 589-602.
61. Gibson NS, Sohne M, Kruip MJ, et al. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost, 2008, 99(1): 229-234.
62. Ceriani E, Combescure C, Le Gal G, et al. Clinical prediction rules for pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost, 2010, 8(5): 957-970.
63. van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet, 2017, 390(10091): 289-297.
64. Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med, 2001, 135(2): 98-107.
65. van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA, 2006, 295(2): 172-179.
66. Kruip MJ, Slob MJ, Schijen JH, et al. Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism: a prospective management study. Arch Intern Med, 2002, 162(14): 1631-1635.
67. Perrier A, Roy PM, Aujesky D, et al. Diagnosing pulmonary embolism in outpatients with clinical assessment, D-dimer measurement, venous ultrasound, and helical computed tomography: a multicenter management study. Am J Med, 2004, 116(5): 291-299.
68. Di Nisio M, Squizzato A, Rutjes AW, et al. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism: a systematic review. J Thromb Haemost, 2007, 5(2): 296-304.
69. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA, 2014, 311(11): 1117-1124.
70. van Es N, van der Hulle T, van Es J, et al. Wells rule and D-dimer testing to rule out pulmonary embolism: a systematic review and individual-patient data meta-analysis. Ann Intern Med, 2016, 165(4): 253-261.
71. Parry BA, Chang AM, Schellong SM, et al. International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs. Thromb Res, 2018, 166: 63-70.
72. Farm M, Siddiqui AJ, Onelöv L, et al. Age-adjusted D-dimer cut-off leads to more efficient diagnosis of venous thromboembolism in the emergency department: a comparison of four assays. J Thromb Haemost, 2018, 16(5): 866-875.
73. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost, 2000, 83(3): 416-420.
74. Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med, 2006, 144(3): 165-171.
75. Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med, 2008, 168(19): 2131-2136.
76. Jimenez D, Lobo JL, Fernandez-Golfin C, et al. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score. Thromb Haemost, 2016, 115(4): 827-834.
77. Hobohm L, Hellenkamp K, Hasenfuß G, et al. Comparison of risk assessment strategies for not-high-risk pulmonary embolism. Eur Respir J, 2016, 47(4): 1170-1178.
78. Becattini C, Agnelli G, Lankeit M, et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur Respir J, 2016, 48(3): 780-786.
79. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J, 2008, 29(18): 2276-2315.
80. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J, 2019, 54(3): 1901647. doi: 10.1183/13993003.01647-2019.
81. Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med, 2005, 172(8): 1041-1046.
82. Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med, 2010, 170(15): 1383-1389.
83. Levi M, Hovingh GK, Cannegieter SC, et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood, 2008, 111(9): 4471-4476.
84. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest, 2016, 149(2): 315-352.
85. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med, 2005, 118(6): 625-635.
86. Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. J Thromb Haemost, 2013, 11(6): 1053-1058.
87. Scherz N, Méan M, Limacher A, et al. Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost, 2013, 11(3): 435-443.
88. Leiss W, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med, 2015, 30(1): 17-24.
89. Frey PM, Méan M, Limacher A, et al. Physical activity and risk of bleeding in elderly patients taking anticoagulants. J Thromb Haemost, 2015, 13(2): 197-205.
90. Donzé J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med, 2012, 125(8): 773-778.
91. Kämpfen P, Méan M, Limacher A, et al. Risk of falls and bleeding in elderly patients with acute venous thromboembolism. J Intern Med, 2014, 276(4): 378-386.
92. Matthews DT, Hemnes AR. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulm Circ, 2016, 6(2): 145-154.
93. van Es J, den Exter PL, Kaptein AA, et al. Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thromb Res, 2013, 132(5): 500-505.
94. Tavoly M, Utne KK, Jelsness-Jørgensen LP, et al. Health-related quality of life after pulmonary embolism: a cross-sectional study. BMJ Open, 2016, 6(11): e013086. doi: 10.1136/bmjopen-2016-013086.
95. Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation, 2014, 130(18): 1636-1661.
96. 柳志红. 2019欧洲心脏病学会《急性肺栓塞诊断和治疗指南》解读. 中国循环杂志, 2019, 34(12): 1155-1157.
97. Cyrino FZ, Bottino DA, Lerond L, et al. Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch. Clin Exp Pharmacol Physiol, 2004, 31(3): 159-162.
98. Bergan JJ, Schmid-Schönbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology, 2001, 52 Suppl 1: S43-S47.
99. Shoab SS, Porter J, Scurr JH, et al. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease—a prospective study. Eur J Vasc Endovasc Surg, 1999, 17(4): 313-318.
100. 国际血管联盟中国分会, 中国老年医学学会周围血管疾病管理分会. 输液导管相关静脉血栓形成防治中国专家共识(2020版). 中国实用外科杂志, 2020, 40(4): 377-383.
101. Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565.
102. 《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南. 中华医学杂志, 2018, 98(36): 2861-2888.
103. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis, 2016, 41(1): 32-67.
104. 傅麒宁, 吴洲鹏, 孙文彦, 等. 《输液导管相关静脉血栓形成中国专家共识》临床实践推荐. 中国普外基础与临床杂志, 2020, 27(4): 412-418.
105. Xu Y, Wang W, Zhao J, et al. Knowledge, attitude, and practice of healthcare professionals toward clinically applying graduated compression stockings: results of a Chinese web-based survey. J Thromb Thrombolysis, 2019, 47(1): 102-108.
106. Lattimer CR, Kalodiki E, Azzam M, et al. Haemodynamic performance of low strength below knee graduated elastic compression stockings in health, venous disease, and lymphoedema. Eur J Vasc Endovasc Surg, 2016, 52(1): 105-112.
107. Ito T, Kukino R, Takahara M, et al. The wound/burn guidelines - 5: guidelines for the management of lower leg ulcers/varicose veins. J Dermatol, 2016, 43(8): 853-868.
108. YY/T 0851-2011. 中华人民共和国医药行业标准: 医用防血栓袜. 国家食品药品监督管理局, 2011.
109. Azirar S, Appelen D, Prins MH, et al. Compression therapy for treating post-thrombotic syndrome. Cochrane Database Syst Rev, 2019, 9(9): CD004177. doi: 10.1002/14651858.CD004177.pub2.
110. Rabe E, Partsch H, Hafner J, et al. Indications for medical compression stockings in venous and lymphatic disorders: an evidence-based consensus statement. Phlebology, 2018, 33(3): 163-184.
111. National Guideline Centre (UK). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. National Institute for Health and Care Excellence (NICE), 2019.
112. 许晓岩, 杨媛华, 王辰. 老年人肺血栓栓塞症的临床表现与分析. 中华老年心脑血管病杂志, 2006, 8(10): 665-667.
113. Lee SY, Ro du H, Chung CY, et al. Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J, 2015, 56(1): 139-145.
114. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax, 2003, 58(6): 470-483.
115. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost, 2010, 8(10): 2105-2112.
116. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation, 2015, 132(3): 194-204.
117. Karamichalakis N, Georgopoulos S, Vlachos K, et al. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol, 2016, 13(8): 718-723.
118. Bartholomew JR. Update on the management of venous thromboembolism. Cleve Clin J Med, 2017, 84(12 Suppl 3): 39-46.
119. Lee KA, Ramaswamy RS. Interventional approaches to deep venous thrombosis. Curr Opin Cardiol, 2017, 32(6): 679-686.
120. CLOTS (Clots in Legs Or sTockings after Stroke) Trial Collaboration. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis after stroke: a randomized trial. Ann Intern Med, 2010, 153(9): 553-562.
121. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J, 1981, 26(2): 115-117.
122. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med, 1982, 10(7): 448-450.
123. Kapoor M, Kupfer YY, Tessler S. Subcutaneous heparin prophylaxis significantly reduces the incidence of venous thromboembolic events in tlle critically ill. Crit Care Med, 1999, 27 Suppl: A69. doi: 10.1097/00003246-199912001-00165.
124. Phung OJ, Kahn SR, Cook DJ, et al. Dosing frequency of unfractionated heparin thromboprophylaxis: a meta-analysis. Chest, 2011, 140(2): 374-381.
125. King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a meta analysis. Chest, 2007, 131(2): 507-516.
126. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e278S-e325S.
127. Dentali F, Douketis JD, Gianni M, et al. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med, 2007, 146(4): 278-288.
128. Che DH, Cao JY, Shang LH, et al. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med, 2013, 24(5): 433-439.
129. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med, 2011, 365(23): 2167-2177.
130. Levine MN, Gu C, Liebman HA, et al. A randomized phase Ⅱ trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost, 2012, 10(5): 807-814.
131. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.
132. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med, 2013, 368(6): 513-523.
133. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage Ⅳ breast cancer. Lancet, 1994, 343(8902): 886-889.
134. Zhang J, Zhang YL, Ma KX, et al. Efficacy and safety of adjunctive anticoagulation in patients with lung cancer without indication for anticoagulants: a systematic review and meta-analysis. Thorax, 2013, 68(5): 442-450.
135. Zhang X, Cai Q, Wang X, et al. Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE). J Thromb Thrombolysis, 2021, 52(3): 863-871.
136. Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol, 2016, 3(2): e64-e71.
137. Lichtenberg MKW, Stahlhoff S, Młyńczak K, et al. Eombosis: a single centre retrospective cohort study. Eur J Vasc Endovasc Surg, 2020, 60(4): 578-585.
138. 吴欣择, 李朝阳, 冯松林, 等. 不同治疗方式对老年急性下肢深静脉血栓形成患者的疗效及预后分析. 血管与腔内血管外科杂志, 2021, 7(3): 292-296.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Chinese expert consensus on the prevention and treatment of venous thromboembolism in the elderly

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content